• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제10권1호
• /
• pp.86-90
• /
• 2007

저자들은 내원 1년 전부터 간헐적인 복통과 함께 복통 시에 항상 동반되는 소량의 비특이적인 설사가 반복되어 내원한 13세 남아에서 직장 유암종을 진단하고 내시경적 절제술로 치료한 증례를 경험하였기에 문헌고찰과 함께 보고한다.

• Journal of Chest Surgery
• /
• 제36권1호
• /
• pp.47-50
• /
• 2003

폐의 카르시노이드 종양은 기관지 상피의 Kulchitsky 세포에서 유래하는 신경내분비 종양이다. 폐의 카르시노이드는 대개는 중심부에 위치한다. 그러나, 비전형적 카르시노이드는 주변부에 위치하기도 하며 조직학적으로 악성도가 높다 흉막에서 기원한 카르시노이드에 대한 보고는 거의 없는 상태로 저자들은 벽측 흉막에 위치하며 폐실질내로의 침윤이 없이 흉벽을 침윤하는 전형적인 카르시노이드를 보고하는 바이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권5호
• /
• pp.2579-2581
• /
• 2016

Background: Neuroendocrine tumors represent 20% of primary lung neoplasms in some registries. According to the WHO classification of 2004, reconsidered for 2015, these lung tumors are divided into 4 groups: typical and atypical carcinoid, small cell and large cell neuroendocrine carcinomas. We report in this paper, for the first time in Lebanon, the distribution and the population characteristics of these tumors. Materials and Methods: This descriptive retrospective study concerned all the pulmonary neuroendocrine tumors (NET) with their characteristics diagnosed in $H\hat{o}tel$ Dieu de France in Beirut, Lebanon from 2001 to 2012, with attention to features like age, gender and subgroup. Results: Of 194 patients with pulmonary NET, 12.4% were typical carcinoid tumors, 3.6% atypical carcinoid, 66.5% small cell lung cancer, 7.7% combined small cell carcinomas and 9.8% large cell neuroendocrine tumors. The mean ages of patients were respectively 51.2 years in typical carcinoid, 64 years in atypical carcinoid, 64.2 years in small cell lung cancers, 67.2 in combined small cell lung cancer and 66.9 in large cells neuroendocrine tumors. The M/F sex ratios were respectively 0.3, 1.3, 1.4, 2.7 and 2.2. Conclusions: The characteristics of lung neuroendocrine tumors in our Lebanese institution are comparable to those reported in the literature.

• Tuberculosis and Respiratory Diseases
• /
• 제43권3호
• /
• pp.440-448
• /
• 1996

Bronchial carcinoid tumors are uncommon, constituting approximately 3-5% of all primary lung cancers. Classification of these tumors has evolved substantially as our understanding of the cellular, biologic, and clinical aspects of these neoplasms has improved. Initially, bronchial carcinoids were thought to be benign and therefore were classified as bronchial adenomas. Currently, however, they are well recognized as having the potential for both local invasion and distant metastatic involvement. Consequently, carcinoid tumors are frankly malignant. Thus bronchial adenoma is a misnomer that should no longer be used for bronchial carcinoids. Most investigators currently favor classifying carcinoid tumors as a type of neuroendocrine neoplasm because of their potential to secrete a variety of chemical substances found in both the central nervous system and the epithelial cells of numerous organs. Bronchial carcinoids are usually characterized by a slow growth pattern and a low incidence of metastasis, and histologically conformed by the azurophil staining and the presence of the characteristic neurosecretary granule on electron microscopy. Atypical carcinoid tumor was first defined by Arrigoni et al, who proposed the following criteria for separation of atypical carcinoid from typical carcinoid tumor : 1) increased mitotic activity with 1 mitotic figure per 1-2 high power fields(or 5-10 mitoses /10 HPF), 2) nuclear pleomorphism, hyperchromatism, and an abnormal nuclear-cytoplasmic ratio, 3) areas of increased cellularity with disorganization of the architecture, and 4) tumor necrosis. In contrast, typical carcinoid tumor may have focal cytologic pleomorphism, but necrosis is absent and mitotic figures are rare. Recently we experienced a case of atypical bronchial carcinoid with multiple distant metastasis, so we report this case with a review of the literature.

• Journal of Chest Surgery
• /
• 제25권5호
• /
• pp.544-549
• /
• 1992

Carcinoid tumors can be ubiquitous, but most will originate in four sites: appendix [38%], small intestine[24%], rectum[13%] or bronchus[11.6%]. And bronchial carcinoids are rare, accounting for only 1% to 6% of all primary lung tumors. Familial adenomatous polyposis cali, the most common form of the polyposis syndromes attributable to a genetic defect, is defined by demonstration of at least 100 adenomatous polyps in the large intestine. We experienced a case of typical bronchial carcinoid with familial adenomatous polyposis cali in 23 year old female patient, which was surgically treated by left lower lobectomy.

• Journal of Digestive Cancer Reports
• /
• 제9권2호
• /
• pp.57-59
• /
• 2021

Carcinoid tumor is called as neuroendocrine tumor and is classified into neuroendocrine tumor Grade 1, neuroendocrine tumor Grade 2, and neuroendocrine carcinoma based on the differentiation of tumors. Recently, the incidence of rectal carcinoid tumor has been increasing probably due to the increased interest on screening colonoscopy and the advancement of endoscopic imaging technology. As the rectal carcinoid shows a wide range of clinical characteristics such as metastasis and long-term prognosis depending on the size and histologic features, it is a challenge to give a consistent diagnostic code in patients with the rectal carcinoid. If the rectal carcinoid tumor is less than 1 cm in size, it can be given as the code of definite malignancy or the code of uncertain malignant potential according to International Classification of Diseases for Oncology (ICD-O) by World Health Organization (WHO). Because patients get different amount of benefit from the insurance company based on different diagnostic codes, this inconsistent coding system has caused a significant confusion in the clinical practice. In 2019, WHO updated ICD-O and Statistics Korea subsequently changed Korean Standard Classification of Diseases (KCD) including the code of rectal carcinoid tumors. This review will summarize what has been changed in recent ICD-O and KCD system regarding the rectal carcinoid tumor and surmise its clinical implication.

• Tuberculosis and Respiratory Diseases
• /
• 제43권4호
• /
• pp.623-629
• /
• 1996

기관지 비정형 카르시노이드 종양은 임파절 및 다른 장기로의 전이율이 높은 질환으로 특별한 증상 없이 우연히 방사선학적 검사상 발견되어 지는 드문 질환으로 알려져 있으며, 수술적 절제술이 우선적 치료로 되어 있다. 저자들은 흥부 방사선적 검사 및 조직 검사로 진단되어 수술적 절제술을 시행한 간전이를 동반한 폐기관지 비정형 카르시노이드 종양 1예를 경험하였기에 보고한다.

• 대한의생명과학회지
• /
• 제17권3호
• /
• pp.197-202
• /
• 2011

Mitosis count is one of the most helpful morphologic features for distinguishing pulmonary typical carcinoid (TC) from atypical carcinoid (AC). However, identifying areas of highest mitotic activity is tedious and time-consuming, and mitosis count may vary substantially among pathologists. Anti-phosphohistone H3 (PHH3) is an antibody that specifically detects histone H3 only when phosphorylated at serine 10 or serine 28, an event that is concurrent with mitotic chromatin condensation and not observed during apoptosis. In this study, immunohistochemical staining for PHH3 was performed to determine whether PHH3 was a reliable and objective mitosis-specific marker for pulmonary carcinoid tumors. Seventeen cases of surgically resected pulmonary carcinoid tumors (12 TCs and 5 ACs) were obtained and classified according to the 2004 World Health Organization classification. Mitotic counts determined by PHH3 correlated to ones determined by hematoxylin and eosin (H&E) staining; however, PHH3 mitotic counts (mean mitotic counts: 1 in TCs and 3.2 in ACs) were slightly higher than H&E mitotic counts (mean mitotic counts: 0.25 in TCs and 1.8 in ACs). The mitotic counts determined by experienced observer were more correlated to those determined by inexperienced observer with the PHH3-based method (R=0.968, P<0.001) rather than H&E staining (R=0.658, P<0.001). These results suggest that the PHH3 mitotic counting method was more sensitive and simple for detecting mitoses compared to traditional H&E staining. Therefore, PHH3 immunohistochemistry may contribute to more accurate and reproducible diagnosis of pulmonary carcinoid tumors and may be a valuable aid for administrating appropriate clinical treatment.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권16호
• /
• pp.6679-6683
• /
• 2014

Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.

• Tuberculosis and Respiratory Diseases
• /
• 제38권1호
• /
• pp.74-82
• /
• 1991

Bronchial carcinoid is one of the unusual tumors of the lung, accounting for 1 percent of all lung tumors. Carcinoids, like small cell carcinomas, are generally considered to be derived from a neurosecretary type of cell of the respiratory epithelium, the Kulchtsky's cell. So, they are no longer classified as bronchial adenoma, and are recently grouped into the neuroendocrine group of tumors, the so-called APUD (Amine Precursor Uptake Decarboxylase) group of tumors. Although usually characterized by a slow growth pattern and a low incidence of metastatic disease, bronchial carcinoids should no longer be considered as beingn, and a much higher malignant behavior has been described with a special destignation of 'atypical carcinoid'. Bronchial carcinoids are histologically confirmed by the azurophil staining and the presence of the characteristic neurosecretary granule on electron microscopy. Recently we experienced two cases of bronchial carcinoid, the first case, being peripheral-located and histologically proven as atypical carcinoid, and the second, being central-located and hitologically typical. So we report these cases with a review of the literature.